Literature DB >> 7521491

NG-nitro-L-arginine contracts vascular smooth muscle by an endothelium-independent mechanism.

Y X Wang1, C C Pang.   

Abstract

We characterized the contractile effect of the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA) in endothelium-denuded rat aortic rings. Incubation with L-NNA (4 x 10(-6)-6.4 x 10(-5) M) for 5 h dose-dependently contracted endothelium-denuded aortic rings. In contrast, incubation with NG-nitro-D-arginine (D-NNA 6 x 10(-6)-4 x 10(-4) M), diphenyleneiodonium (DPI, NO synthase inhibitor, 3.2 x 10(-6) M) or dexamethasone (10(-7) M, inhibitor of expression of inducible NO synthase) did not contract the denuded rings. The L-NNA-induced contraction was not significantly altered by the presence of the endothelium or by pretreatment with L-arginine (L-Arg 2 x 10(-3) M) or lipopolysaccharide (100 ng/ml). These results suggest that L-NNA causes slow contraction of endothelium-denuded vascular smooth muscle (VSM) by a mechanism independent of the inhibition of constitutive or inducible NO biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521491     DOI: 10.1097/00005344-199407000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids.

Authors:  R L Matz; M A de Sotomayor; C Schott; J C Stoclet; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat.

Authors:  M Alvarez De Sotomayor; M D Herrera; E Marhuenda; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  Endothelial nitric oxide modulates perivascular sensory neurotransmission in the rat isolated mesenteric arterial bed.

Authors:  Vera Ralevic
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.